Phase 1/2 × Completed × Leukemia, Myelomonocytic, Chronic × Clear all Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2 Completed
73 enrolled 12 charts
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
Phase 1/2 Completed
55 enrolled 19 charts
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Phase 1/2 Completed
82 enrolled 15 charts
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Phase 1/2 Completed
28 enrolled 8 charts
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Phase 1/2 Completed
63 enrolled 16 charts
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Phase 1/2 Completed
50 enrolled 17 charts
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase 1/2 Completed
66 enrolled 10 charts
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Phase 1/2 Completed
55 enrolled 15 charts
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Phase 1/2 Completed
45 enrolled
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Phase 1/2 Completed
30 enrolled
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Phase 1/2 Completed
113 enrolled 21 charts
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Phase 1/2 Completed
17 enrolled 14 charts
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Phase 1/2 Completed
21 enrolled
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Phase 1/2 Completed
37 enrolled
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Phase 1/2 Completed
106 enrolled
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
Phase 1/2 Completed
25 enrolled 13 charts
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
Phase 1/2 Completed
37 enrolled 14 charts
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Phase 1/2 Completed
31 enrolled
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Phase 1/2 Completed
37 enrolled
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
Phase 1/2 Completed
60 enrolled 5 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Phase 1/2 Completed
92 enrolled 5 charts
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Phase 1/2 Completed
Bevacizumab in Treating Patients With Myelodysplastic Syndrome
Phase 1/2 Completed
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Phase 1/2 Completed
47 enrolled
Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome
Phase 1/2 Completed
26 enrolled
Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Phase 1/2 Completed
37 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
Phase 1/2 Completed
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
Phase 1/2 Completed
76 enrolled
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase 1/2 Completed
32 enrolled
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase 1/2 Completed
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
Phase 1/2 Completed
30 enrolled
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Phase 1/2 Completed